Allergic Rhinitis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 179
Inquire Before Buying

Global Markets Direct's, ‘Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

  • The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

  • The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Allergic Rhinitis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Allergic Rhinitis Overview 9
Therapeutics Development 10
Pipeline Products for Allergic Rhinitis - Overview 10
Pipeline Products for Allergic Rhinitis - Comparative Analysis 11
Allergic Rhinitis - Therapeutics under Development by Companies 12
Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16
Allergic Rhinitis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Allergic Rhinitis - Products under Development by Companies 20
Allergic Rhinitis - Products under Investigation by Universities/Institutes 25
Allergic Rhinitis - Companies Involved in Therapeutics Development 26
3M Drug Delivery Systems 26
Accolade Pharmaceuticals, LLC 27
AFFiRiS AG 28
ALK-Abello A/S 29
Allergy Therapeutics Plc 30
Ampio Pharmaceuticals, Inc. 31
Array BioPharma Inc. 32
ASIT biotech s.a. 33
Axikin Pharmaceuticals, Inc. 34
Chong Kun Dang Pharmaceutical Corp. 35
Chrysalis BioTherapeutics, Inc. 36
ELORAC, Inc. 37
Faes Farma, S.A. 38
Fountain Biopharma Inc. 39
GlaxoSmithKline Plc 40
Glenmark Pharmaceuticals Ltd. 41
HAL Allergy BV 42
Hisamitsu Pharmaceutical Co., Inc. 43
Johnson & Johnson 44
Laboratorios LETI S.L. 45
Ligand Pharmaceuticals, Inc. 46
Marinomed Biotechnologie GmbH 47
Merck & Co., Inc. 48
Panmira Pharmaceuticals, LLC. 49
Paradigm Biopharmaceuticals Limited 50
Pfizer Inc. 51
Protectimmun GmbH 52
Roxall Medizin GmbH 53
Sanofi 54
Shionogi & Co., Ltd. 55
Stallergenes Greer plc 56
Sun Pharma Advanced Research Company Ltd. 57
Taiho Pharmaceutical Co., Ltd. 58
VentiRx Pharmaceuticals, Inc. 59
Xencor, Inc. 60
Allergic Rhinitis - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 65
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
(azelastine hydrochloride + budesonide) - Drug Profile 71
(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 72
(levocabastine hydrochloride + mometasone furoate) - Drug Profile 73
854-A - Drug Profile 74
Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile 75
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 76
Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 77
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 78
Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 79
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 80
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 81
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 82
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 84
AM-211 - Drug Profile 85
AM-461 - Drug Profile 86
Ampion - Drug Profile 87
AR-460770 - Drug Profile 95
Arabinogalactan - Drug Profile 96
asapiprant - Drug Profile 97
B-244 - Drug Profile 98
beta-escin - Drug Profile 99
bilastine - Drug Profile 100
budesonide - Drug Profile 102
CBP-174 - Drug Profile 103
cidoxepin hydrochloride - Drug Profile 104
clustoid wiesenlieschgras - Drug Profile 105
desloratadine - Drug Profile 106
emedastine difumarate - Drug Profile 108
esketamine hydrochloride - Drug Profile 109
FB-825 - Drug Profile 112
gp-ASIT - Drug Profile 113
GSK-2245035 - Drug Profile 115
GSP-301 - Drug Profile 117
Lactococcus lactis G121 - Drug Profile 118
motolimod - Drug Profile 119
nasapaque - Drug Profile 122
pentosan polysulfate sodium - Drug Profile 123
PF-06444752 - Drug Profile 125
PF-06444753 - Drug Profile 127
Pollinex Quattro Tree - Drug Profile 129
rE58 - Drug Profile 131
Small Molecule for Allergic Rhinitis - Drug Profile 132
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 133
Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 134
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 135
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 136
STAGR-120 - Drug Profile 137
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 138
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 140
SUN-0597 - Drug Profile 145
TAS-205 - Drug Profile 147
Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 148
VTX-1463 - Drug Profile 149
XmAb-7195 - Drug Profile 150
Zafi-3 - Drug Profile 151
Allergic Rhinitis - Dormant Projects 152
Allergic Rhinitis - Discontinued Products 162
Allergic Rhinitis - Product Development Milestones 165
Featured News & Press Releases 165
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175

List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2016 15
Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Development by Companies, H2 2016 (Contd..4) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2016 30
Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 31
Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2016 32
Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2016 33
Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 34
Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35
Allergic Rhinitis - Pipeline by Array BioPharma Inc., H2 2016 36
Allergic Rhinitis - Pipeline by ASIT biotech s.a., H2 2016 37
Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016 38
Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 39
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 40
Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2016 41
Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 42
Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2016 43
Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2016 44
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 45
Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2016 46
Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 47
Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2016 48
Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2016 49
Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 50
Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016 51
Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 52
Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 53
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 54
Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 55
Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2016 56
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2016 57
Allergic Rhinitis - Pipeline by Sanofi, H2 2016 58
Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 59
Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2016 60
Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 61
Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 62
Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 63
Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2016 64
Assessment by Monotherapy Products, H2 2016 65
Assessment by Combination Products, H2 2016 66
Number of Products by Stage and Target, H2 2016 68
Number of Products by Stage and Mechanism of Action, H2 2016 70
Number of Products by Stage and Route of Administration, H2 2016 72
Number of Products by Stage and Molecule Type, H2 2016 74
Allergic Rhinitis - Dormant Projects, H2 2016 156
Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 157
Allergic Rhinitis - Dormant Projects (Contd..2), H2 2016 158
Allergic Rhinitis - Dormant Projects (Contd..3), H2 2016 159
Allergic Rhinitis - Dormant Projects (Contd..4), H2 2016 160
Allergic Rhinitis - Dormant Projects (Contd..5), H2 2016 161
Allergic Rhinitis - Dormant Projects (Contd..6), H2 2016 162
Allergic Rhinitis - Dormant Projects (Contd..7), H2 2016 163
Allergic Rhinitis - Dormant Projects (Contd..8), H2 2016 164
Allergic Rhinitis - Dormant Projects (Contd..9), H2 2016 165
Allergic Rhinitis - Discontinued Products, H2 2016 166
Allergic Rhinitis - Discontinued Products (Contd..1), H2 2016 167
Allergic Rhinitis - Discontinued Products (Contd..2), H2 2016 168

List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2016 15
Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 65
Assessment by Combination Products, H2 2016 66
Number of Products by Top 10 Targets, H2 2016 67
Number of Products by Stage and Top 10 Targets, H2 2016 67
Number of Products by Top 10 Mechanism of Actions, H2 2016 69
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 69
Number of Products by Top 10 Routes of Administration, H2 2016 71
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 71
Number of Products by Molecule Types, H2 2016 73
Number of Products by Stage and Molecule Types, H2 2016 73
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Rhino-Conjunctivitis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Rhino-Conjunctivitis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Rhino-Conjunctivitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Allergic Rhinitis - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Allergic Rhinitis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Allergic Rhinitis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Allergic Rhinitis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with th......
  • Birch Pollen Allergy-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Birch Pollen Allergy-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Birch Pollen Allergy. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Seasonal Allergic Rhinitis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Seasonal Allergic Rhinitis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Seasonal Allergic Rhinitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, colla......
  • Cat Allergy-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Cat Allergy-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Cat Allergy. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundi......
  • Cedar Pollen Allergy-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Cedar Pollen Allergy-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Cedar Pollen Allergy. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Perennial Allergic Rhinitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Perennial Allergic Rhinitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Perennial Allergic Rhinitis Report is to understand the market and pipeline status of the drugs around the Perennial Allergic Rhinitis to explore the generic development opportunities, licensing opportunities an......
  • Allergies-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Type I Hypersensitivity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Type I Hypersensitivity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Type I Hypersensitivity Report is to understand the market and pipeline status of the drugs around the Type I Hypersensitivity to explore the generic development opportunities, licensing opportunities and to gain co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs